Caplin Point Laboratories Limited has reshaped its senior leadership structure with the appointment of D. Muralidharan as Whole-Time Director and the re-appointment of Dr. Sridhar Ganesan as Managing Director. The Board of Directors approved these changes on August 12, 2026, based on the recommendation of the Nomination and Remuneration Committee. Both appointments are subject to approval by shareholders at the company’s ensuing Annual General Meeting (AGM).

The procedural filings were made pursuant to Regulation 30 read with Schedule III of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The disclosures also comply with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as well as BSE Circular no. LIST/COMP/14/2018-19 and NSE Circular no. NSE/CML/2018/24, both dated June 20, 2018.

Leadership Changes

The Board approved the following key appointments:

• Dr. Sridhar Ganesan (DIN: 06819026) was re-appointed as Managing Director for a further period of two years, effective from August 25, 2026, to August 24, 2028.
• D. Muralidharan (DIN: 08301904) was appointed as Whole-Time Director for a period of two years, effective from August 12, 2026, to August 11, 2028. He will continue to serve as Chief Financial Officer (CFO) in addition to his new designation.

Executive Profiles

Dr. Sridhar Ganesan brings over 35 years of global leadership experience in the pharmaceutical industry. His expertise spans profit centre management, global marketing, international business development, project planning, production, new product development, quality assurance, and factory management. He has held leadership positions across South Asia, the Middle East, and Africa, providing strategic direction for the company’s growth and global expansion.

Mr. D. Muralidharan has served as the company’s CFO since February 19, 2016. He holds a Bachelor’s degree in Commerce, Associate Membership of the Institute of Company Secretaries of India (ICSI), and a Cost & Management Accountant qualification from the Institute of Cost Accountants of India (ICMAI). He is also a member of the Risk Management Committee.

Compliance Disclosures

Both directors are not debarred from holding office by virtue of any SEBI order or other authority. No relationships between the directors were disclosed in connection with these appointments.

The appointments reflect the company’s focus on retaining experienced leadership in both strategic operations and financial management. Shareholders will vote on these resolutions at the upcoming AGM.

Caplin Point Laboratories has fixed September 18, 2026, as the record date for its 35th Annual General Meeting (AGM). The Board of Directors approved this timeline during a meeting held on August 12, 2026, ensuring shareholders holding equity shares on the specified date are eligible to attend the meeting and vote on resolutions. This determination also establishes the eligibility criteria for the payment of any final dividend declared for the financial year 2025-26.

The AGM is scheduled to take place on September 25, 2026. Shareholders must hold equity shares with a face value of ₹2 each in their demat accounts or physical holdings as of the close of business on the record date to participate in the proceedings. This procedural step is critical for investors seeking to exercise their voting rights or receive dividend entitlements, if approved by the shareholders during the meeting.

Key Dates and Details

The announcement was made pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company notified both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Ltd (NSE) regarding the intimation. Venkatram G, General Counsel & Company Secretary of Caplin Point Laboratories, signed the disclosure document.

What This Means for Investors

For retail and institutional investors, the record date acts as the cutoff for dividend entitlements. Any shares sold after September 18, 2026, will not carry the right to the final dividend for FY25-26, while shares purchased before this date will retain that entitlement. Investors should ensure their shareholdings are updated in their demat accounts prior to the record date to avoid any discrepancies in eligibility.

The final dividend amount, if declared, will be determined during the AGM on September 25, 2026. The company has not yet disclosed the proposed dividend per share, leaving the exact payout subject to shareholder approval at the upcoming meeting.